Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
13 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Other Events
10 Apr 24
8-K
Cost Associated with Exit or Disposal Activities
4 Apr 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX
8 Mar 24
8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Regulation FD Disclosure
7 Dec 23
8-K
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Other Events
13 Oct 23
8-K
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Other Events
26 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
22 Feb 24
S-8
Registration of securities for employees
10 Aug 23
S-8
Registration of securities for employees
13 Mar 23
S-3ASR
Automatic shelf registration
13 Mar 23
424B4
Prospectus supplement with pricing info
7 Oct 22
S-1MEF
Registration of additional securities for an S-1
6 Oct 22
S-1
IPO registration
4 Oct 22
DRS
Draft registration statement
24 Aug 22
S-8
Registration of securities for employees
12 Jan 22
424B4
Prospectus supplement with pricing info
10 Jan 22
Other
UPLOAD
Letter from SEC
20 Dec 23
CORRESP
Correspondence with SEC
19 Dec 23
UPLOAD
Letter from SEC
5 Dec 23
EFFECT
Notice of effectiveness
7 Oct 22
CORRESP
Correspondence with SEC
4 Oct 22
CORRESP
Correspondence with SEC
4 Oct 22
UPLOAD
Letter from SEC
31 Aug 22
EFFECT
Notice of effectiveness
7 Jan 22
SEC STAFF
SEC staff action: Order
6 Jan 22
CERT
Certification of approval for exchange listing
6 Jan 22
Ownership